Skip to main content

Market Overview

CEPI, VBI Vaccines Collaborate To Develop COVID-19 Vaccine Candidates Against Variants


The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines Inc (NASDAQ: VBIVentered into a partnership for the development of VBI's enveloped virus-like particle (eVLP) vaccine candidates against SARS-CoV-2 variants, including the South African B.1.351 variant, also known as 501Y.V2.

  • CEPI is an international coalition set up to prepare for future infectious disease threats.
  • It will provide up to $33 million to support the advancement of VBI-2905, a monovalent eVLP candidate, through Phase 1 development. Phase 1 trial will start in mid-year 2021.
  • As part of the agreement, this funding will also support the preclinical expansion of additional multivalent vaccine candidates. 
  • VBI Vaccines is advancing a suite of coronavirus vaccine candidates under the VBI-2900 program, developed in collaboration with the National Research Council of Canada.
  • An adaptive Phase 1/2 study of VBI-2902 is already ongoing at nine clinical sites in Canada.
  • Price Action: VBIV shares are up 10.2% at $3.47 in premarket trading on the last check Wednesday.

Related Articles (VBIV)

View Comments and Join the Discussion!

Posted-In: Biotech News Penny Stocks Health Care Financing Contracts Small Cap FDA

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at